Rekah Pharmaceutical Industry Ltd.

Tel Aviv Stock Exchange REKA.TA

Rekah Pharmaceutical Industry Ltd. Return on Equity (ROE) for the year ending December 31, 2023: -4.44%

Rekah Pharmaceutical Industry Ltd. Return on Equity (ROE) is -4.44% for the year ending December 31, 2023, a -252.35% change year over year. Return on equity measures profit against shareholder equity; higher ROE indicates superior profitability and value creation.

Rekah Pharmaceutical Industry Ltd. Return on Equity (ROE) for the year ending December 31, 2022 was -1.26%, a -132.93% change year over year.
Rekah Pharmaceutical Industry Ltd. Return on Equity (ROE) for the year ending December 31, 2021 was 3.83%, a -41.30% change year over year.
Rekah Pharmaceutical Industry Ltd. Return on Equity (ROE) for the year ending December 31, 2020 was 6.52%, a 267.34% change year over year.
Rekah Pharmaceutical Industry Ltd. Return on Equity (ROE) for the year ending December 31, 2019 was 1.78%, a -61.75% change year over year.

Key data

Date	Return on Equity (ROE)	Return on Capital Employed (ROCE)	Interest Coverage Ratio	Debt to Equity Ratio

Tel Aviv Stock Exchange: REKA.TA

Rekah Pharmaceutical Industry Ltd.

CEO	Mr. Mordechai Elgrabli
IPO Date	Aug. 12, 2002
Location	Israel
Headquarters	30 Hamelach Street
Employees	427
Sector	Health Care
Industries Pharmaceuticals Cosmetics Drugstores & Retail Pharmacies

Description

Rekah Pharmaceutical Industry Ltd. engages in the manufacture, marketing, sale, and distribution of prescription and OTC drugs, dermo-cosmetics, vitamins, and nutritional supplements in Israel. The company offers steroid tablets; antibiotics, including penicillin and cephalosporin; drops and ointments to treat allergies, infections, and dryness of the eyes; baby products; and dermatological preparations. Its portfolio of products comprise approximately 280 drugs used in various medical fields. Rekah Pharmaceutical Industry Ltd. was founded in 1941 and is based in Holon, Israel.

Key trends

Past 5 years